The Roche Covid-19 Nasal Rapid Antigen Self Test Kit provides reliable results for individuals suspected of having
COVID-19. The Self Test can be performed by the general public, providing another option for decentralised testing.
- High test quality and performance
- Faster results compared to laboratory testing
- No need to visit a healthcare professional or schedule an appointment
- Reduced handling errors and waste
- Increased user protection – virus inactivation by extraction buffer after 2 minutes
- Brought to you by Roche Diagnostics. Included on the Australian Register of Therapeutic Goods (ARTG 352250)
The
Roche Covid-19 Nasal Rapid Antigen Self Test Kit is a lateral flow test for the qualitative detection of
SARS-CoV-2 nucleocapsid antigen in human nasal samples. This test is used to detect antigens of the
SARS-CoV-2 virus in individuals suspected of having
COVID-19 and is designed as a self-test for the general public.
Benefits of kit
A
SARS-CoV-2 antigen test detects the presence of the
SARS-CoV-2 virus from part of the upper respiratory tract swab specimens by identifying a nucleoprotein that is carried by the virus. The test identifies current infection during the acute phase of
COVID-19, while the virus is still present in large quantities in the respiratory tract.
Testing is possible everywhere
Decentralised testing minimises the possibility of exposure of healthcare workers to potentially infected individuals while protecting healthcare capacity.
Tool to safely re-open the economy
Tested individuals might be able to travel and participate in events, while reducing the risk of spreading the virus.
Real-world evidence
Independent performance studies with large sample sizes, including professional collection, self-collection and self-testing groups.
